In the world of cancer research, time means everything. This industry can be very exciting, but it can also be very demanding. Unlike the programs on television, it can take years before a drug becomes approved. Clay Siegall, M.D., is one of the leaders in cancer research, and he has a stellar track-record of success. Siegall is the CEO of a biotech-oncology company named Seattle Genetics. This company has been around since 1998, and it has definitely served cancer patients with its advanced medications. Siegall has put a lot of time, a lot of money and a lot of effort into this program and as of today, it is paying-off in huge returns.
One of the biggest business moves for Seattle Genetics is its international marketing. This guy has spent hours and hours studying this particular subject because he wants the company to expand in a major way. Though Seattle Genetics was founded on rigorous research as well as founded on drug development, the company is looking to become a pharmaceutical powerhouse. By owning the international-marketing rights of its medications, the sky is the limit because Seattle Genetics will now be able to fulfill its destiny. Siegall is already the holder of more than 10 patents. These patents will help the company retain its generated income. In a sense, Siegall has modeled this company after Ultragenyx. Ultragenyx is a biopharmaceutical company that focuses on producing medications for debilitating diseases. Being as cost-efficient as possible is the goal and both of these two companies are doing just that.
Siegall is also very accomplished thanks to his Ph.D in Genetics as well as his B.S. in Biology. He has written up to 70 health-related publications, and he has won numerous industry-related awards. Cancer patients has been benefiting from the effects of Dr. Clay Siegall, and he will continue to perfect his craft even more in the years to come.